Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006, for AVI BioPharma, Inc. (Note: The request metadata listed "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is in the development stage, focusing on antisense therapeutics. It has incurred cumulative losses since its inception in 1980 and has not generated material revenue from product sales.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 | Six Months Ended June 30, 2006 | Balance Sheet (June 30, 2006) |
|---|---|---|---|
| Revenues | $18,558 | $84,520 | N/A |
| Net Loss | $(6,902,029) | $(15,963,179) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.31) | N/A |
| Operating Expenses | $7,437,640 | $17,022,611 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $31,764,383 |
| Short-term Securities | N/A | N/A | $12,709,104 |
| Total Current Assets | N/A | N/A | $45,101,376 |
| Total Current Liabilities | N/A | N/A | $2,264,821 |
| Accumulated Deficit | N/A | N/A | $(188,611,423) |
Material Changes vs. Prior Period
- Revenue: Revenue decreased to $18,558 in Q2 2006 from $39,317 in Q2 2005, primarily due to lower grant revenues. For the six-month period, revenue remained essentially flat at approximately $85,000.
- Operating Expenses: Expenses increased significantly to $7.44 million in Q2 2006 from $5.19 million in Q2 2005. For the six months ended June 30, 2006, expenses rose to $17.02 million from $10.78 million in the prior year period.
- Drivers of Expense Increase:
- Stock-Based Compensation: Adoption of SFAS 123R increased net loss by approximately $1.0 million in Q2 and $2.1 million for the six months.
- R&D Costs: Increases were driven by higher employee costs, clinical expenses for hepatitis C and coronary artery bypass grafting programs, and GMP subunit production costs.
- Chiron Agreement: Approximately $500,000 in stock was issued to Chiron Corporation as a milestone payment, expensed to R&D.
- Interest Income: Net interest income increased to $517,053 in Q2 2006 from $215,725 in Q2 2005 due to higher average cash balances and interest rates.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: The company believes it has sufficient cash to fund operations through 2007. It expects 2006 expenditures to be approximately $22 million to $25 million. Additional financing will be required beyond 2007.
- Government Funding: The 2006 defense appropriations act allocated $11 million for the company's defense-related programs (Ebola, Marburg, dengue, anthrax, ricin). This funding has not yet been received and is not reflected in the financial statements.
- Strategic Agreements:
- Cook Group Inc.: Entered into agreements for development and commercialization of vascular/cardiovascular products. Received net proceeds of $4.96 million from the sale of 692,003 shares.
- Chiron Corporation: Secured a nonexclusive license for hepatitis C therapeutics, issuing stock valued at $500,000 as the first milestone payment.
- Risks: The company is in a development stage with no assurance of achieving profitable operations. Success depends on completing product development, obtaining regulatory approvals, and securing additional financing. There is a risk that planned products will not be commercially successful.
Investor Verification Checklist
- Company Identity: Verify that the filing is for AVI BioPharma, Inc., not Sarepta Therapeutics (as indicated in the request metadata).
- Accounting Changes: Review the impact of the January 1, 2006 adoption of SFAS 123R on stock-based compensation expenses and net loss.
- Government Grants: Confirm the status and receipt of the $11 million defense appropriations funding mentioned in the outlook.
- Collaboration Milestones: Monitor future royalty and milestone payments associated with the Cook Group and Chiron agreements.
- Cash Burn Rate: Assess the sufficiency of the $44.5 million in cash and short-term securities against the projected $22-$25 million expenditure for 2006.